

FORM PTC-1449 (Modified)	12/03/99	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: OPHD-03282	Serial No.: 09/095,536
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)		Applicant: John A. Kink		
		Filing Date: 06/10/98		Group Art Unit: 1646
(37 CFR § 1.98(b))				

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Pattee	Class	Subclass	Filing Date
FH	1	5,654,407	08/05/97	Boyle <i>et al.</i>	530	388.15	05/05/95
	2	5,436,154	07/25/95	Barbanti <i>et al.</i>	435	240.27	12/13/91
	3	5,385,901	01/31/95	Kaplan <i>et al.</i>	514	231.5	10/02/92
	4	4,870,163	09/26/89	Rubin <i>et al.</i>	530	413	08/29/85
	5	5,656,272	08/12/97	Le <i>et al.</i>	424	133.1	02/04/94

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

	Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation	
						Yes	No
FH	6	WO 96/33204	24.10.96	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

FH	7	Machiedo <i>et al.</i> , "Patterns of Mortality in a Surgical Intensive Care Unit," <i>Surg. Gyn. & Obstet.</i> 152:757-759 (1981)
	8	Morris <i>et al.</i> , "Endotoxemia in neonatal calves given antiserum to a mutant <i>Escherichia coli</i> (J-5)," <i>Am. J. Vet. Res.</i> 47:2554-2565 (1986)
	9	Hoffman <i>et al.</i> , "Prognostic Variables for Survival of Neonatal Foals Under Intensive Care," <i>J. Vet. Int. Med.</i> 6:89-95 (1992)
	10	Wolff, "Monoclonal Antibodies and the Treatment of Gram-Negative Bacteremia and Shock," <i>New Eng. J. Med.</i> 324:486-488 (1991)
	11	K.A. Schulman <i>et al.</i> , "Cost-effectiveness of HA-1A Monoclonal Antibody for Gram-Negative Sepsis," <i>JAMA</i> 266:3466-3471 (1991)
	12	K. Ohlsson <i>et al.</i> , "Interleukin-1 receptor antagonist reduces mortality from endotoxin shock," <i>Nature</i> 348:550-552 (1990)
	13	R.C. Bone, "The Pathogenesis of Sepsis," <i>Ann. Intern. Med.</i> 115:457-469 (1991)
	14	K.J. Tracey <i>et al.</i> , "Shock and Tissue Injury Induced by Recombinant Human Cachectin," <i>Science</i> 234:470-474 (1986)
	15	A. Tewari <i>et al.</i> , "Preliminary report: effects of interleukin-1 on platelet counts," <i>Lancet</i> 336:712-714 (1990)
	16	S.M. Opal <i>et al.</i> , "Efficacy of a Monoclonal Antibody Directed against Tumor Necrosis Factor in Protecting Neutropenic Rats from Lethal Infection with <i>Pseudomonas aeruginosa</i> ," <i>J. Infect. Dis.</i> 161:1148-1152 (1990)
	17	Polson <i>et al.</i> , "Antibodies to Proteins from Yolk of Immunized Hens," <i>Immunol. Comm.</i> , 9:495 (1980)
	18	C. Galanos <i>et al.</i> , "Galactosamine-induced sensitization to the lethal effects of endotoxin," <i>Proc. Natl. Acad. Sci. USA</i> 76:5939-5943 (1979)
	19	J. Rothe <i>et al.</i> , "Mice lacking the tumor necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by <i>Listeria monocytogenes</i> ," <i>Nature</i> 364:798-802 (1993)
	20	S.Q. DeJoy <i>et al.</i> , "Effect of CL 184,005, a Platelet-Activating Factor Antagonist in a Murine Model of <i>Staphylococcus aureus</i> -Induced Gram-Positive Sepsis," <i>J. Infect. Dis.</i> 169:150-156 (1994)
	21	Opal <i>et al.</i> , "Potential Hazards of Combination Immunotherapy in the Treatment of Experimental Septic Shock," <i>J. of Infectious Diseases</i> 173:1415-1421 (1996)
	22	Russell <i>et al.</i> , "Combined Inhibition of Interleukin-1 and Tumor Necrosis Factor in Rodent Endotoxemia: Improved Survival and Organ Function," <i>J. of Infectious Diseases</i> 171:1528-1538 (1995)
	23	Plevy <i>et al.</i> , "A Role for TNF- α and Mucosal T Helper-1 Cytokines in the Pathogenesis of Crohn's Disease," <i>J. of Immunology</i> 159:6277-6282 (1997)
	24	Van Dullemen <i>et al.</i> , "Treatment of Crohn's Disease With Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2)," <i>Gastroenterology</i> 109:129-138 (1995)
	25	Targan <i>et al.</i> , "A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease," <i>NEJM</i> , 337:1029-1035 (1997)

Examiner: *FH*Date Considered: *12/11/95*

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: OPHD-03282	Serial No.: 09/095,536
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR § 1.98(b))				Applicant: John A. Kink	
				Filing Date: 06/10/98	Group Art Unit:
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)					
26	Elliott <i>et al.</i> , "Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid arthritis," <i>Lancet</i> 344:1105-1110 (1994)				
27	Elliott <i>et al.</i> , "Repeated therapy with monoclonal antibody to tumor necrosis factor α (cA2) in patients with rheumatoid arthritis," <i>Lancet</i> 344:1125-1127 (1994)				
28	Kojouharoff <i>et al.</i> , "Neutralization of tumor necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice," <i>Clin Exp Immunol</i> 107:353-358 (1997)				
29	Olson <i>et al.</i> , "Antiserum to Tumor Necrosis Factor and Failure to Prevent Murine Colitis," <i>J Ped Gastroenterology Nutrition</i> 21:410-418 (1995)				
30	Zacharchuk <i>et al.</i> , "Macrophage-mediated cytotoxicity: Role of a soluble macrophage cytotoxic factor similar to lymphotoxin and tumor necrosis factor," <i>PNAS USA</i> 80:6341-6345 (1983)				
31	Zacharchuk, Charles Michael, "A Macrophage Cytotoxic Factor: Immunochemical and Functional Characterization," Dissertation Abstract				
32	Pennica <i>et al.</i> , "Human tumor necrosis factor: precursor structure, expression and homology to lymphotoxin," <i>Nature</i> 312:724-729 (1984)				
33	Ruff, Michael Roland, "Mechanism of Action of a Serum Oncolytic Protein, Rabbit Tumor Necrosis Factor," Dissertation Abstract				
34					
35					
36					
37					
38					
39					
40					
41					
42					
43					
44					
45					
46					
47					
48					
49					
50					
51					
52					
53					
54					
55					
Examiner:	<i>Tom Hamed</i>		Date Considered:	06/17/98	
EXAMINER:	Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

FORM PTO-1449 (Modified)			U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: OPHD-03282	Serial No.: 09/095,536	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR § 1.98(b))			Applicant: John A. Kink				
			Filing Date: 06/10/98		Group Art Unit: 1646		
U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Subclass	Filing Date	
JK	1	5,420,253	5/30/95	Emery et al.	530	423	9/09/93
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)							
	2	Doherty <i>et al.</i> , "Evidence for IFN- γ as a Mediator of the Lethality of Endotoxin and Tumor Necrosis Factor- α ," <i>J. Immunology</i> 149(5):1666-1670 (1992)					
	3	Manthey <i>et al.</i> , "The role of cytokines in host responses to endotoxin," <i>Reviews in Medical Microbiology</i> 3(2):72-79 (1992)					
	4	Starnes <i>et al.</i> , "Anti-IL-6 Monoclonal Antibodies Protect Against Lethal Escherichia coli Infection and Lethal Tumor Necrosis Factor- α challenge in mice," <i>J. of Immun.</i> 145(12):4185-4191 (1990)					
	5						
	6						
	7						
	8						
	9						
	10						
	11						
	12						
	13						
	14						
	15						
	16						
	17						
	18						
	19						
	20						
	21						
	22						
	23						
	24						
	25						
Examiner: <i>John Kink</i>				Date Considered: 12/17/95			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

